OrigAMI-5

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

Oct 19, 2025 → Oct 25, 2026

Cited window

Oct 19, 2025 → Oct 25, 2026

Retrieved

Oct 31, 2026

Title

A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants With Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Registry

NCT07276399

Study IDs

61186372HNC3001 · 2025-521917-24-00 (EUCT number)

Sponsor

Janssen Research & Development, LLC

Design

Phase 3 · Interventional, randomized, parallel

Status

Recruiting

Enrollment

500 estimated

Registered

2025-12-11

Start

2025-12-03 actual

Primary completion

2029-06-18 estimated

Primary endpoint

Overall Survival (OS)

Interventions

5 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –Not yet captured in this edition: a view on limitations of target-lesion-based response assessment in recurrent/metastatic head and neck cancer.
• –Not yet captured in this edition: a remark on the trial’s launch, untreated HPV-unrelated recurrent/metastatic population and randomized treatment comparison.
• –Not yet captured in this edition: a view on patient selection for first-line treatment of recurrent head and neck cancer after prior definitive therapy.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –178 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
• –Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
• –The sources reviewed for this edition are not a representative sample of HCP opinion. Educational sessions can appear in multiple formats, and posts may relay the same underlying remarks.
• –Coverage favored trial identifiers and names. Discussions of the same clinical decision without those references, including older discussions, may be underrepresented, and some potentially relevant passages were not fully assessed.
• –No full protocol or exact-trial results publication was available for this report. The drug's regulatory context was not comprehensively assessed, so reported eligibility, dosing, monitoring and approval expectations are not confirmed protocol or regulatory rules.
• –Most efficacy enthusiasm concerns OrigAMI-04 or other early clinical experience, often single-arm, small and compared with historical expectations. It cannot establish OrigAMI-5 comparative benefit or harm.
• –Source publication dates can differ from session or presentation dates. Differences between dated accounts do not by themselves demonstrate a change of mind.
• –Some passages cannot be assigned to a named speaker. Program titles, participant lists and professional profiles do not resolve who spoke those passages.
• –Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
• –PD-L1 eligibility accounts differ, and one combination-experience assertion sits alongside discussion of an amivantamab–paclitaxel cohort. These statements are preserved as expressed rather than silently reconciled.
• –A compressed complete-response comparison leaves the ownership of a 15% figure unclear, and reported reaction rates and observation practices concern different cohorts or settings.
• –Detailed strategies for populations outside the HPV-negative/HPV-unrelated first-line decision are not developed in this narrative; their statements remain available separately.
• –The forthcoming frontline cohort-5 triplet account and parts of the alternative-bispecific efficacy and response-durability discussion are not fully covered here. Comparisons among these options therefore remain incomplete.

How reports are built and checked: Methods.

Last checked for new commentary Oct 31, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update. No corrections.

Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.

Help me decide whether to buy the Erudio report "OrigAMI-5" (NCT07276399), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.

1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "origami-5-07276399". If you cannot make requests, read https://www.erudio.com/reports/origami-5-nct07276399.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT07276399", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct07276399 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.

When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.

curl https://www.erudio.com/reports/origami-5-nct07276399.json
curl https://www.erudio.com/reports/origami-5-nct07276399.md

# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "origami-5-07276399" })